# Paper Weekly advances

## 18.10.2021 - 22.10.2021

### Paper briefly read (Intro/Conclusion)

* [An evaluation of enasidenib for the treatment of acute myeloid leukemia](https://www-tandfonline-com.proxy.insermbiblio.inist.fr/doi/full/10.1080/14656566.2019.1654456)  
Area covered: This review describes the mechanisms of action, the pharmacodynamic and pharmacokinetic properties, the safety, and efficacy of enasidenib. Phase I/II/III clinical trials are also reported and discussed.   
\-\> To read

* [Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications](https://www-tandfonline-com.proxy.insermbiblio.inist.fr/doi/full/10.1080/10428194.2019.1602260)  
This review will focus on the underlying biological mechanism and clinical relevance of IDH mutations in cancer.   
\-\> Not urgent

* [Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
](https://journals.lww.com/hemasphere/Fulltext/2021/06000/Targeting_IDH1_and_IDH2_Mutations_in_Acute_Myeloid.14.aspx)  
PERSPECTIVE: an update on targeting IDH-mutated AML is provided    
\-\> Not urgent

* [Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma](https://exonpublications.com/index.php/exon/article/view/300)  
Current understanding of the biological roles of wild-type and mutant IDH enzymes in glioblastoma. We discuss the challenges hampering the development of IDH targeted therapeutics and the current status of IDH1 mutant inhibitor development    
\-\> To read ++

* [The impact of mitochondria on cancer treatment resistance](https://link.springer.com/article/10.1007/s13402-021-00623-y) available on sci-hub   
REVIEW     
\-\> To read

### Selected paper



---------

## 24.10.2021 - 29.10.2021
